Patents by Inventor Patrick Hearing
Patrick Hearing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210332331Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.Type: ApplicationFiled: February 4, 2021Publication date: October 28, 2021Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
-
Patent number: 10947514Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.Type: GrantFiled: January 23, 2019Date of Patent: March 16, 2021Assignee: The Research Foundation For The State University Of New YorkInventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
-
Publication number: 20190292525Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.Type: ApplicationFiled: January 23, 2019Publication date: September 26, 2019Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
-
Patent number: 10214730Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.Type: GrantFiled: July 9, 2015Date of Patent: February 26, 2019Assignee: The Research Foundation For The State University Of New YorkInventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
-
Publication number: 20160002607Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.Type: ApplicationFiled: July 9, 2015Publication date: January 7, 2016Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
-
Publication number: 20140155469Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.Type: ApplicationFiled: April 19, 2012Publication date: June 5, 2014Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
-
Publication number: 20140140962Abstract: The invention provides compositions and methods for making and using modified viruses, including infectious viruses, having an external surface linked to at least one heterologous unnatural moiety that is exemplified by unnatural amino acid and unnatural saccharide. The unnatural moiety that is linked to the invention's modified viruses is optionally further linked to a molecule of interest (such as probe, cytotoxin, therapeutic molecule, antibody, affibody, epitope, etc. The invention's compositions and methods for use in, for example, diagnostic applications and therapeutic applications such as gene therapy, oncolytic therapy, and/or vaccine therapy.Type: ApplicationFiled: April 26, 2012Publication date: May 22, 2014Applicant: The Research Foundation of State University of New YorkInventors: Isaac Sheridan Carrico, Banerjee Partha, Patrick Hearing, Oum Yoon Hyeun
-
Patent number: 7585498Abstract: The present invention relates to recombinant Adenoviruses (Ad) which function as helper viruses to gutted Ad viruses lacking viral coding sequences. The recombinant Ad of the present invention comprise a binding site of the E. coli Lac repressor protein embedded within the packaging domain. Available Lac repressor protein binds to its operator site within the helper virus packaging domain, precluding the binding of natural packaging factors. The present invention also provides recombinant Ad which in addition to having a binding site for the Lac repressor protein within the packaging domain, also comprise coding sequence for the Lac repressor protein under the control of a promoter which functions in producer cells. Methods for suppressing packaging of helper Ad during packaging of a gutted Ad vector are also provided as are methods of producing recombinant helper Ad using lactose or lactose derivative as a regulatory molecule. Temperature shift may also be used to regulate growth of a recombinant helper Ad.Type: GrantFiled: September 25, 2002Date of Patent: September 8, 2009Assignee: The Research Foundation of State University of New YorkInventors: Patrick Hearing, Amy Ostrom, Susanne Wells
-
Patent number: 7563617Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.Type: GrantFiled: May 12, 2005Date of Patent: July 21, 2009Assignee: The Research Foundation Of State University of New YorkInventors: Patrick Hearing, Wadie F. Bahou, Ziv Sandalon, Dmitri V. Gnatenko
-
Publication number: 20060073595Abstract: The present invention relates to recombinant Adenoviruses (Ad) which function as helper viruses to gutted Ad viruses lacking viral coding sequences. The recombinant Ad of the present invention comprise a binding site of the E. coli Lac repressor protein embedded within the packaging domain. Available Lac repressor protein binds to its operator site within the helper virus packaging domain, precluding the binding of natural packaging factors. The present invention also provides recombinant Ad which in addition to having a binding site for the Lac repressor protein within the packaging domain, also comprise coding sequence for the Lac repressor protein under the control of a promoter which functions in producer cells. Methods for suppressing packaging of helper Ad during packaging of a gutted Ad vector are also provided as are methods of producing recombinant helper Ad using lactose or lactose derivative as a regulatory molecule. Temperature shift may also be used to regulate growth of a recombinant helper Ad.Type: ApplicationFiled: September 25, 2002Publication date: April 6, 2006Inventors: Patrick Hearing, Amy Ostrom, Susanne Wells
-
Publication number: 20060008884Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.Type: ApplicationFiled: May 12, 2005Publication date: January 12, 2006Applicant: The Research Foundation of State University of New YorkInventors: Patrick Hearing, Wadie Bahou, Ziv Sandalon, Dmitri Gnatenko
-
Patent number: 6916635Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.Type: GrantFiled: February 12, 2001Date of Patent: July 12, 2005Assignee: The Research Foundation of State University of New YorkInventors: Patrick Hearing, Wadie F. Bahou, Ziv Sandalon, Dmitri V. Gnatenko
-
Publication number: 20020102731Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.Type: ApplicationFiled: February 12, 2001Publication date: August 1, 2002Applicant: The Research Foundation of State University of New YorkInventors: Patrick Hearing, Wadie F. Bahou, Ziv Sandalon, Dmitri V. Gnatenko